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Abstract
Evaluation of expression profile in autism spectrum disorder (ASD) patients is an important approach to understand possible
similar functional consequences that may underlie disease pathophysiology regardless of its genetic heterogeneity. Induced
pluripotent stem cell (iPSC)-derived neuronal models have been useful to explore this question, but larger cohorts and
different ASD endophenotypes still need to be investigated. Moreover, whether changes seen in this in vitro model reflect
previous findings in ASD postmortem brains and how consistent they are across the studies remain underexplored questions.
We examined the transcriptome of iPSC-derived neuronal cells from a normocephalic ASD cohort composed mostly of
high-functioning individuals and from non-ASD individuals. ASD patients presented expression dysregulation of a module
of co-expressed genes involved in protein synthesis in neuronal progenitor cells (NPC), and a module of genes related to
synapse/neurotransmission and a module related to translation in neurons. Proteomic analysis in NPC revealed potential
molecular links between the modules dysregulated in NPC and in neurons. Remarkably, the comparison of our results to a
series of transcriptome studies revealed that the module related to synapse has been consistently found as upregulated in
iPSC-derived neurons—which has an expression profile more closely related to fetal brain—while downregulated in
postmortem brain tissue, indicating a reliable association of this network to the disease and suggesting that its dysregulation
might occur in different directions across development in ASD individuals. Therefore, the expression pattern of this network
might be used as biomarker for ASD and should be experimentally explored as a therapeutic target.
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Introduction
It has been long recognized that genetic factors play an
important role in autism spectrum disorder (ASD) [1, 2], a
neurodevelopmental disorder characterized by impairments
in social-communicative skills and repetitive behaviors, that
affects at least 1% of the population [3, 4]. Although the
knowledge regarding genetic risk factors for ASD has
greatly improved in recent years [5], mainly driven by the
development of high-throughput genomic screening
approaches, the complex genetic architecture and the het-
erogeneity of etiological factors underlying the disorder
hamper the understanding of its pathophysiology, the
establishment of molecular diagnostic criteria, and the
identification of potential therapeutic targets. On the other
hand, despite the large number of ASD-candidate genes
described so far, they seem to converge on a few final
common effectors or molecular pathways [6], suggesting
that the different genetic variants associated with the disease
may lead to similar functional consequences, which might
be reflected in the transcriptional level, protein level or,
lately, in the regulation of specific cellular mechanisms.
Based on this premise, whole transcriptome studies have
been conducted to explore differentially expressed gene
profiles associated with ASD, mainly using postmortem
brain tissue from autistic individuals [7–10]. Although
consistent results have been found across some of these
studies, such as expression alterations of genes related to
immune response, neurotransmission and neurodevelop-
ment, it has to be considered that the child/adult brain may
not capture dysregulated gene expression associated with
ASD that are only transiently present during prenatal
development. In this regard, the research on the pathogen-
esis of neurodevelopmental disorders, including ASD, has
benefited from the cellular reprogramming technique. This
approach has enabled the generation of neural progenitor
cells (NPC) and neurons from ASD patients, therefore
producing in vitro models that might recapitulate the fea-
tures of the developing brain in vivo [11–15]. Some studies
using iPSC-derived neuronal cells have explored tran-
scriptome profiles of relatively small samples of idiopathic
ASD individuals, including two studies that have selected
only macrocephalic patients [16, 17], who represent less
than 20% of the ASD patients [18], and a study on a sample
enriched with low-functioning normocephalic patients [19].
Considering the genetic and phenotypic heterogeneity of the
disease, further studies are needed to increase the number of
examined patients, specially to investigate other ASD
endophenotypes, and to clarify the correlation between the
results found in postmortem brain tissue and those found
using in vitro neuronal models.
Here, we generated iPSC lineages from stem cells
derived from exfoliated deciduous teeth (SHED) of a cohort
of ASD patients enriched with high-functioning individuals
to investigate the transcriptional profiles of iPSC-derived
neuronal cells at two stages of development: at progenitor
state and after complete differentiation to post-mitotic
neurons. We examined which temporal window of brain
development best fits our in vitro model by comparing the
transcriptome profile of the iPSC-derived neural cells with
expression profiles of fetal brains at different stages of
development and also to adult postmortem brains. Differ-
ences between ASD and control samples were addressed
both on a single gene and on a systemic level, using gene
co-expression network analysis. Comparison of our results
with previous transcriptome studies using both iPSC-
derived neuronal cells and postmortem brain tissue
revealed the consistent dysregulation of a module of
synaptic molecules, which may represent a subset of genes
exhibiting a pattern of expression that could be used as a
biomarker for ASD.
Materials and methods
Patients ascertainment
All ASD individuals enrolled in this study (n= 6) were
males and negative for Fragile-X Syndrome, including five
high-functioning patients and one low-functioning patient
(IQ < 70; Supplementary Table S1). The control sample
consisted of 6 male individuals with no history of ASD or
any other neurodevelopmental disorder diagnosis. This
project has been approved by the Ethics Committee of the
Instituto de Biociências – Universidade de São Paulo
(protocol number 1.133.486).
array-CGH and exome sequencing
The presence of CNVs was evaluated in peripheral blood
DNA from patients and their parents by comparative
genomic hybridization array (CGH-array) using an Agilent
4X 180K chip (Agilent Technologies, CA, USA). Exome-
sequencing libraries were generated using Nextera Rapid
Capture Exome kit (Illumina, CA, USA) and sequenced on
an Illumina HiSeq 2500 equipment. Reported variants were
selected based on a pipeline described in Supplementary
Material.
iPSC generation and characterization
iPSCs lines were generated from stem cells from human
exfoliated deciduous teeth (SHED) through retroviral
transduction of vectors containing SOX2, c-Myc, OCT4, and
KLF4 as described in Griesi-Oliveira et al. [14]. Two to
three clones were generated from each sample, which were
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tested for pluripotency markers expression and for endo-
derm, mesoderm and ectoderm markers expression after
random differentiation (Supplementary Fig. S1; Supple-
mentary Material).
Neuronal differentiation
Neuronal progenitor cells (NPC) were differentiated from
iPSC as described in Griesi-Oliveira et al. [14], and main-
tained in 0.5x NB media—DMEM/F12 (Thermo Fisher
Scientific, CA, USA), plus 0.5x N2-supplement (Thermo
Fisher Scientific), and 0.5x B27 serum (Thermo Fisher
Scientific)—supplemented with 20 ng/ml of FGF and EGF
(Peprotech, NJ, USA; Supplementary Fig. S1A). Some NPC
lineages were transduced with SYN::EGFP lenti-virus vec-
tor, a vector containing the sequence of green fluorescent
protein under the control of the Synapsin gene promoter
(kindly donated by Dr. Alysson Muotri). Neurons were
obtained after 4 weeks of differentiation from NPC (Sup-
plementary Fig. S1A), using 1x NB media, supplemented
with 1 μM of retinoic acid (Sigma-Aldrich, MI, USA). This
protocol has been previously proven to generate neurons
with active electrophysiological properties [14]. GFP-
expressing neurons were sorted out from heterogeneous
populations of differentiated neuronal cells by fluorescence-
activated cell sorting in a FACSAria II Machine (BD
Biosciences, NJ, USA; Supplementary Fig. S2).
Immunocytochemistry
Cells were fixed and then incubated overnight with one of
the primary antibodies: anti-SOX2 (1:100, Millipore, MA,
USA; cat# AB5603), anti-Nestin (1:250, Millipore; cat#
MAB5326), anti-CTIP2 (1:500, Millipore; cat# ab187668),
anti-MAP2 (1:500, Millipore; cat# MAB3418), anti-GFP
(Millipore, 1:1000; cat# ab1218). The cells were then
stained with Alexa Fluor 488 donkey or Alexa Fluor 594
donkey anti-mouse (Thermo Fisher Scientific, cat# A21202
and A21203, respectively) and visualized with Olympus
IX51 confocal microscope (Olympus, Japan).
RNA sequencing and normalization of expression
data
RNA samples from NPC (29 cell lines), from heterogeneous
populations of neuronal cells (16 cell lines) or sorted GFP-
expressing neurons (7 cell lines) were used for library pre-
paration using the TruSeq RNA Sample Preparation kit
(Illumina, CA, USA) and then sequenced on a HiSeq 2500
(Illumina) to generate 100 bp paired-end sequences.
Sequences were aligned to the reference human genome
(hg19) using TopHat2 [20] and read counts per gene were
summarized using HTSeq [21]. Data are available at Gene
Expression Omnibus website under the accession number
GSE142670. After neuronal proportion estimation by a
deconvolution method [22] (Supplementary Material), four
neuronal samples with a calculated proportion of neurons
lower than 51% were excluded (Supplementary Table S2).
Only genes with a Fragments per million kilobase (FPKM) ≥
1 in more than half of the samples (calculated separately for
NPC and neurons) were considered as expressed and
retained for analysis (NPC: 13818 genes; neurons: 15026
genes). Expression data were normalized using RUVseq [23]
in order to correct for different proportions of neurons within
each sample. We checked for the best parameters (control
genes and number of co-variates) that would lead to the loss
of such correlation (Supplementary Table S3), while leading
to the best clustering of replicates (Supplementary Figure S3;
see Supplementary Methods).
Prediction of regional identity and developmental
period
To estimate the maturity of the cells and their regional
identity, transcriptome profiles of each of NPC and neuron
samples were compared with the transcriptome data of brain
samples available at BrainSpan Atlas [24] (www.brainspan.
org), whose ages vary between 4 post-conceptional weeks
until 60 years old, using a machine-learning approach
developed by Stein et al. [25] (https://context.semel.ucla.
edu/).
Differential expression and weighted-gene
correlation network analysis
Differentially expressed genes were identified using dream
statistical model available within variancePartition package
[26], considering a significance level threshold of FDR ≤ 0.05.
Weighted-gene co-expression network analysis was per-
formed separately for NPC and Neurons using WGCNA
package from R [27] (Supplementary Material). For each
module, gene expression levels of each sample were sum-
marized in an eigengene value which was then used to assess
the correlation of a module to disease status, the batch of
library preparation or the neuronal proportion within the
samples. Functional annotation analysis was performed using
the Database for Annotation, Visualization and Integrated
Discovery 6.8 (DAVID - https://david-d.ncifcrf.gov/), Inge-
nuity Pathway Analysis Software (http://www.ingenuity.com/)
and/or cameraPR function from limma package [28].
Protein–protein enrichment test was performed using STRING
(https://string-db.org/cgi/input.pl). Module-preservation ana-
lysis [29] was conducted using modulePreservation function
from WGCNA, comparing our data with BrainSpan fetal
brain samples. Data and analysis code are available at https://
github.com/griesik/ASDiPSCTranscriptome.
Transcriptome of iPSC-derived neuronal cells reveals a module of co-expressed genes consistently. . .
Neuronal morphological analysis
Twenty thousand cell-sorted GFP-expressing neurons were
plated with 50,000 cells of a heterogeneous population of
neuronal cells differentiated from NPC not transduced with
SYN::EGFP either from the same individual (non-mixed
condition) or from an individual from the opposite group
(mixed condition), in wells of an 8-well chamber slide.
Seventy-two hours after plating, cells were fixed and
immunostained for green fluorescent protein, as described
above. Images were taken at ×20 with InCell Analyzer 2200
microscope (GE Healthcare, Chicago IL, USA) and mor-
phological analysis was conducted using Neurphology
plugin from ImageJ. Measures obtained were normalized by
the number of nuclei in each image and statistical analysis
was performed using geepack package from R [30].
Mass spectrometry-based proteomics
Protein was extracted from NPC of 6 clones (3 patients, 3
controls) and injected into two-dimensional, reverse-phase
liquid chromatography using an Acquity UPLC M-Class
System (Waters Corporation, MA, USA) coupled to a
Synapt G2-Si mass spectrometer (Waters Corporation).
Mass spectrometric raw data was processed with Progen-
esis®QI version 2.1 (Waters Corporation) and proteins were
identified. Quantitative data were processed using dedicated
algorithms and searched against the Uniprot human pro-
teomics database (https://www.uniprot.org/proteomes/),
with the default parameters for ion accounting and quanti-
tation as described in Cassoli et al. [31].
Variants and Sfari genes enrichment analysis
A list of rare de novo exonic variants found in ASD indi-
viduals and their siblings was obtained from Kosmick et al.
[32] (a compilation of the original papers from de Rubeis
et al. [33]; Iossifov et al. [34]). ASD genes were compiled
from Sfari [35] database (as of November 2019) and a list of
ID genes was obtained from ID genetics [36] (http://www.
ccgenomics.cn/IDGenetics/index.php), as of January 2019
(see Supplementary Methods). Only the protein-coding
genes from the co-expression modules were considered for
gene set enrichment, which was performed using a two-
sided Fisher’s exact test calculated by the R function fisher.
test, corrected for false discovery rate.
Module overlap analysis
The function userListEnrichment from WGCNA was used
to evaluate the overlap between the modules identified in
our study to modules identified by others [8–10, 16, 17,
19, 37–39]. For identification of a list of genes with strong
evidence of being part of the module of synapse genes
associated with ASD, we considered all the modules from
the studies that used either fetal/neonatal brain samples or
iPSC-derived neurons that presented a significant overlap
with MNeu1-turquoise, except for the study from DeRosa
et al. [19] (see Supplementary Methods).
Results
Genetic characterization of ASD patients
DNA from peripheral blood samples from all the patients
included in this study was submitted to array-CGH and whole-
exome sequencing. We identified two individuals carrying
more than one ASD pathogenic variant, suggestive of an oli-
gogenic model of inheritance. Patient F2613 harbors a 345 kb
de novo duplication in 17p13.3, which involves six different
genes: ABR, BHLHA9, TUSC5, YWHAE, CRK, MYO1C.
Duplications in this region are well described in the literature
[40], and although associated with variable phenotypes and
incomplete penetrance, a considerable number of individuals
with this copy number variation (CNV) present ASD. This
patient also carries a de novo missense variant predicted to be
damaging (CADD ≥ 20) in DOCK1 (NM_001290223:
c.4838C>T (p.Pro1613Leu)) [41] an ASD-candidate gene
(Sfari score= 3). The other patient, F2688, is a compound
heterozygote for rare potentially deleterious missense variants
(NM_005045.3: c.7538C>G (p.Ser2513Cys) and c.7634C>T
(p.Ala2545Val)) inherited from his parents in the Reelin gene
(RELN), which is considered a high confidence ASD-
candidate (Sfari= 1). These variants lead to reduced secre-
tion of Reelin and impaired Reelin signal transduction in
iPSC-derived NPC of this patient, as we have recently
described [42]. This patient also harbors a rare de novo loss-
of-function (LoF) mutation in another ASD-candidate gene,
CACNA1H (Sfari score= 2), which affects a splicing site in
exon 13 of this gene. Rare de novo LoF mutations in brain
expressed genes considered to be LoF-intolerant (pLI ≥ 0.8, as
described in ExAC database, http://exac.broadinstitute.org/) or
de novo missense variants with CADD-score ≥ 20 were not
identified in any of the other four remaining patients. On the
other hand, inherited rare potentially damaging (CADD ≥ 20)
missense variants were identified in Sfari genes in all the
patients. A full description of this genetic characterization is
available in Supplementary Table S4.
iPSC-derived neuronal cells have an expression
profile similar to fetal brains at a developmental
period important to ASD pathophysiology
In order to characterize the neuronal cells obtained from
ASD and control iPSC lines using our differentiation
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protocol, we conducted several analyses. First, we showed
that NPC express Nestin and SOX2, while neurons express
CTIP2 and MAP2, which are typical cell markers for these
cell types (Fig. 1a, b, g). Differentiation protocols may not
produce pure populations of the cells of interest and,
therefore, the proportion of cells of different types may vary
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across samples, leading to biased results in gene expression
profiling studies [43, 44]. Indeed, we found that the
first component of the expression profile of each sample
was strongly correlated with the proportion of neurons
within the sample before normalization (Supplementary
Figure S3).
Once transcriptome data were corrected for this bias (see
the Materials and methods section), we first conducted a
differential expression analysis between NPC and neurons
(using all controls and ASD cells), which revealed that, as
expected, genes that were downregulated in neurons after
differentiation from NPC are mainly involved in cell cycle
and cell proliferation, while upregulated genes are related to
the process of neurogenesis (Fig. 1c, d; Supplementary
Table S5). We then used CoNTExT framework [25], a
machine-learning-based algorithm trained on transcriptome
data from BrainSpan Atlas [24], to estimate the stage of
brain development and the brain regional identity of our
iPSC-derived neuronal cells. While transcriptome profiles
from NPC best reflects in vivo neuronal tissue from fetal
brains at 4–10 post-conception weeks (pcw) and are most
likely to be of cortical identity, the neurons, after 4 weeks of
differentiation from NPC, best reflect a mid-fetal period
(16–24 pcw) and have an expression profile more similar to
cerebellar cortex, evidencing a temporal progression of
neuronal differentiation (Fig. 1e, f). Importantly, the mid-
fetal temporal window has already been shown to be a
critical period for ASD pathophysiology [45]. Finally, using
panels of specific cell-type markers, we found that our
neuronal culture is characterized by the presence of
GABAergic and glutamatergic neurons, with no evidence
for the presence of oligodendrocytes and dopaminergic or
serotoninergic neurons (Fig. 1g; Supplementary Table S5).
All these results validate our differentiation protocol and
transcriptional data, particularly revealing that the neurons
derived using this protocol have a transcriptional profile
more similar to fetal brains of a specific developmental
window that is relevant for ASD risk.
Transcriptome analysis reveals altered gene
expression in ASD that correlates with neuronal
morphological abnormalities
Since we have multiple clones for each individual, we then
applied a statistical model that accounts for a repeated
measurement design [26] to properly control the false dis-
covery rate in the identification of differentially expressed
genes (DEGs) between ASD and control neuronal cells. In
NPC, we did not identify any gene with differential
expression that reached statistical significance (Supple-
mentary Table S6), while in neurons, we found 20 genes
with significant expression dysregulation (multiple testing
corrected p < 0.05, Supplementary Table S7). Remarkably,
three of these genes (KCNB1, SLC12A5, CHMP1A) are
associated with ASD according to Sfari database. These low
numbers of statistically significant DEGs are not unex-
pected in a heterogeneous disease such ASD, as not
necessarily all patients will have expression dysregulation
of the exact same genes. Based on that, we applied a
functional enrichment method for our data set not focused
on specific set of genes defined by an arbitrary p-value, but
instead, that evaluates if a set of genes involved in a par-
ticular function is highly ranked relative to other genes in
terms of differential expression [28]. We found that, in
NPC, the highly ranked upregulated genes are enriched
within functions related to translational process, mitochon-
drion organization and function and cell cycling (Fig. 2a,
Supplementary Table S6). On the other hand, in neurons,
synapse, neurotransmitter release, as well as actin filament
and dendrite extension regulation are the biological pro-
cesses and pathways found as enriched for highly ranked
upregulated genes (Fig. 2b, Supplementary Table S7). The
highly ranked downregulated genes in both NPC and neu-
rons were not found as enriched within any biological
process or canonical pathway (Supplementary Tables S6
and S7).
In order to functionally validate these expression differ-
ences, we analyzed morphological phenotypes in ASD and
control neurons. For that, after four weeks of differentiation
from NPCs, we sorted the GFP-expressing neurons, re-
plated them in low density with non-GFP-expressing
population of differentiated neuronal cells either from the
same individual (non-mixed condition—NM) or from an
individual from the opposed group (mixed condition—M),
and cultured the cells for 4 more days to have extended
neurites again (Fig. 2c, d). In the non-mixed condition, we
found that ASD neurons showed the same number of
neurites per cell as compared with controls, but these
neurites displayed ~68% less ramifications (p= 0.008) and
were ~65% shorter (p= 0.005; Fig. 2c, d; Supplementary
Table 8). Interestingly, when the neurons of the patients
were co-cultured with control-derived populations of
Fig. 1 Characterization of neuronal cells derived from ASD and
control iPSC lines. a, b iPSC-derived neuronal cells show expression
of typical markers for progenitor cells, such as SOX2 and Nestin, and
for neurons, such as MAP2 and CTIP2. c, d Differential expression
analysis reveal that genes downregulated upon differentiation of NPC
into neurons are related to cell cycle and cell division, while genes
related to neuronal differentiation and function are upregulated. For
this analysis all control and ASD samples were used. e, f Temporal and
regional identity of iPSC-derived neuronal cells as predicted by the
machine-learning algorithm CoNTExT: NPC display a transcriptome
profile similar to in vivo fetal brain samples at 4–10 post-conceptional
weeks (pcw), while neurons best match the 16–24 pcw temporal
window, evidencing a clear temporal progression in the maturation of
the obtained cells. g Average expression of select cell-type markers for
neurons, astrocytes and oligodendrocytes as well as for glutamatergic,
gabaergic, serotoninergic, and dopaminergic neurons.
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neuronal cells, there was an improvement of neurite mor-
phology: in comparison to the non-mixed condition, the
number of ramifications and the length of the neurites of
ASD neurons increased ~22% (p= 0.016 and p < 0.001,
respectively), which, however, is still slightly different from
control neurons (p < 0.05; Fig. 2c, d; Supplementary
Fig. 2 Functional annotation analysis of differentially expressed
genes in NPC and neurons from ASD individuals. a Functional
annotation analysis shows that top upregulated genes in ASD NPC are
enriched (red) within Gene Ontology (GO) terms and canonical
pathways related to ribosome biogenesis, translation regulation and
mitochondrion function. b Top ranked upregulated genes in ASD
neurons (red) are enriched within GO terms and pathways related to
synaptic signaling, neurotransmitter release and dendrite extension. A
full description of the functional annotation analysis is available in
Supplementary Tables 6 and 7. c Illustrative images of ASD neurons
co-cultured with non-GFP neurons from the same individual or non-
GFP neurons from a control, and control neurons co-culture with non-
GFP neurons from the same individual or from an ASD individual.
d Box plots showing the quantification of soma size, neurites per cell,
number of ramifications per cell and neurite length for all these
conditions. NMP: non-mixed patient (n= 3 clones); MP: mixed
patient (n= 3 clones); NMC: non-mixed control (n= 5 clones); MC:
mixed control (n= 5 clones). At least eight photos per individual per
condition were analyzed.
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Table 8). Although we found no differences in the number
of neurites per ASD-derived neuron compared with controls
in the non-mixed condition, this number was increased
when the neurons were co-cultured with control population
(p < 0.001; Fig. 2d; Supplementary Table 8). On the other
hand, no difference was noted in these parameters when
control neurons were co-cultured with ASD population of
neuronal cells compared with the non-mixed condition
(Fig. 2d; Supplementary Table 8). These morphological
abnormalities functionally corroborate the expression
changes found in genes related to dendrite extension and
actin cytoskeleton dynamics in ASD neurons. Moreover,
the slightly improvement achieved in such morphological
parameters once ASD neurons were co-cultivated with
control neurons suggests an impairment in neuronal sig-
naling, another function found as enriched for highly ranked
upregulated genes in our transcriptome analysis (Fig. 2b,
Supplementary Table S7).
Networks of co-expressed genes implicated in
translational processes and neurotransmission
are associated with ASD
As previously mentioned, in a heterogeneous disease such
as ASD, it is not expected that different patients will have
dysregulation of the same set of genes, but instead, they
might present dysregulation of different genes that partici-
pates in a same functional network. Therefore, in order to
explore the data in a system level context, we used
weighted-gene co-expression network analysis (WGCNA)
[27] to identify groups of co-regulated genes in NPC and
neurons. We also conducted a module-preservation analysis
[29] in order to validate the biological nature of the detected
modules and evaluate whether NPC and neurons co-
expression networks were consistently well preserved in
fetal brain cortices at 4–10 pcw and at 16–24 pcw, which
are, respectively, the fetal periods best correlated with our
iPSC-derived neuronal cell transcriptome profiles.
In NPC, we identified 11 modules of co-expressed genes
(Fig. 3a; Supplementary Table S9), most of which are
moderately (2 < Zscore < 10) or strongly (Zscore < 10) pre-
served in transcriptome data from fetal brain cortices at
4–10 pcw (Fig. 3b). One of these modules, MNPC10-blue, is
significantly correlated with disease status (Pbonferroni=
0.044; Supplementary Table S9), presenting as upregulated
in ASD individuals (Fig. 3e). MNPC10-blue is enriched for
genes related to protein biosynthesis, RNA processing and
splicing, and mitochondrial function (Fig. 3f).
Twenty modules of co-expressed genes were identified in
neurons, which showed moderate to strong evidence of
preservation in fetal brain cortices at 16–24 pcw (Fig. 3c, d).
Two of these modules, MNeu1-turquoise and MNeu18-purple,
were found to be significantly correlated with the disease
status (Supplementary Table S10). They presented a sig-
nificant inverse correlation (cor=−0.79, p= 4 × 10−5),
showing that they have an inverse co-expression relation-
ship. MNeu18-purple (Pbonferroni= 0.048) is downregulated
in ASD patients (Fig. 3h) and is enriched for genes related
to translational processes and regulation of gene expression
(Fig. 3i). MNeu1-turquoise (Pbonferroni= 0.02), on the other
hand, is upregulated in ASD individuals (Fig. 3k).
Accordingly, its functional annotation showed similar
results to the gene-by-gene differential expression analysis:
MNeu1-turquoise is enriched for genes related to synapse,
ion channels, neurotransmission, and genes involved in
signaling pathways important to neuronal function, such as
GABA receptor signaling and axonal guidance signaling
(Fig. 3l; Supplementary Table S10).
Importantly, the biological nature of these three ASD-
associated modules is supported by protein–protein inter-
action evidence (Fig. 3g, j, m) and by strong to moderate
evidence of module preservation in fetal brain cortices
(MNPC10-blue: Z-score= 16; MNeu18-purple: Z-score= 3;
MNeu1-turquoise: Z-score= 9.9; Fig. 3b, d).
Upregulation of MNPC10-blue in NPC may trigger
expression alteration of ASD-associated modules in
neurons during neuronal differentiation by changes
in translational level
We then hypothesized that the overexpression of MNPC10-
blue in ASD NPC could trigger the dysregulation of key
molecules from MNeu1-turquoise or MNeu18-purple early
in neuronal differentiation (before the establishment of these
co-expression modules) and thus, as the differentiation pro-
cess proceeds, the altered expression of these genes would
lead to the dysregulation of the entire modules, as they start
to emerge in patients’ neurons. To explore this possible
relationship, we first addressed whether MNPC10-blue genes
would act as upstream regulators of MNeu1-turquoise or
MNeu18-purple, but we did not find any MNPC10-blue gene
whose downstream targets are significantly enriched for
genes belonging to the two neuron modules (Supplementary
Table S11). Considering that MNPC10-blue is mainly com-
posed of genes involved in translational processes, we
hypothesized that the dysregulation of this module at the
transcription level could be leading to an aberrant expression
of specific proteins in NPC which, in turn, might control the
expression of MNeu1-turquoise or MNeu18-purple genes.
Thus, we conducted a proteomic study in NPC of 3 ASD
patients and 3 control individuals and found that two
differentially expressed proteins in ASD NPC, EWSR1
(Panova= 0.02, fold change= 1.48) and APP (Panova= 0.04,
fold change= 1.5), are upstream regulators of a significant
number of MNeu1-turquoise genes (Fig. 4; p < 0.05, see
Supplementary Table S11).
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Next, to further explore the possible regulatory links
between these modules, we verified the correlation between
the NPC protein expression levels and MNPC10-blue,
MNeu1-turquoise and MNeu18-purple module eigengenes of
the same samples included in the proteomic analysis. We
found 14 proteins whose expression levels are significantly
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correlated to both MNPC10-blue and MNeu1-turquoise mod-
ule eigengenes and 6 proteins with significant correlation to
MNPC10-blue and MNeu18-purple module eigengenes
(Fig. 4, Supplementary Table S11). The expression levels of
two of these proteins are significantly correlated to module
eigengenes of the three modules: EIF4H, which is upregu-
lated in ASD NPC (Panova= 0.003, fold change= 3.5), and
LAMB1, which is downregulated in ASD NPC (Panova=
0.02, fold change= 1.5). Remarkably, EIF4H is also a
member of MNPC10-blue and interacts with the MNeu1-
turquoise upstream regulator EWSR1 (Fig. 4; Supplemen-
tary Table 11). Taken together, these exploratory analyses
point to some putative proteins that may act as molecular
links between NPC and neuron transcriptome dysregulation
seen in ASD patients.
Genetic evidence supports the association of
MNeu1-turquoise with ASD
Taking advantage of the large exome-sequencing datasets of
ASD families already published [33, 34], we examined
whether individuals with ASD (n= 3982) had an increased
burden of de novo LoF or rare missense variants compared
with their siblings (n= 2078) in any of the modules iden-
tified either in NPC or neurons, particularly those that were
found as ASD-associated. We only considered LoF variants
in LoF-intolerant genes (pLi ≥ 0.8) and missense variants
predicted to be potentially damaging by CADD-score
(CADD ≥ 20). We observed that ASD patients show a
marginally increased burden of LoF variants in MNeu1-
turquoise genes (p= 0.044, OR= 6.8, Supplementary
Table S12), which does not exceed the statistical sig-
nificance after FDR correction (Padj= 0.36, Fig. 5a). It is
interesting to note that among the 2078 control subjects in
this cohort, only one female individual shows a LoF variant
in a MNeu1-turquoise gene (JAKMIP1), which is also shared
with her male ASD sibling, while 13 out of 3982 ASD
patients harbor LoF variants in MNeu1-turquoise genes
(Supplementary Table S12), showing that, despite the lack
of significance, a much higher proportion of ASD patients
presents LoF variants in genes belonging to this module
than control individuals. In addition, we unexpectedly
found an increased burden of LoF variants in ASD patients
in genes from a module associated with chromatin and
transcription regulation identified in NPC (Supplementary
Table S9), module MNPC1-turquoise, which did not present
expression dysregulation in our patients (Fig. 5a, Supple-
mentary Table S12).
In our cohort in particular, although we did not identify
any rare de novo disrupting variant of strong effect in
MNPC10-blue, MNeu1-turquoise, or MNeu18-purple genes in
any of the six patients, we identified some inherited rare
potentially damaging variants in genes of these modules,
which are described in Supplementary Table S4.
We next asked whether any of the modules of co-
expressed genes identified in NPC and neurons are enriched
for ASD-risk genes compiled by the Sfari database (https://
gene.sfari.org/). We observed an enrichment of Sfari genes
(“Sfari all”, Fig. 5a) in three neuron modules: MNeu1-
turquoise (FDR= 0.004, OR= 1.94), MNeu2-tan (FDR=
8.9 × 10−7, OR= 2.7), and MNeu14-red (FDR= 0.04, OR
= 2.04). Because intellectual disability (ID) is frequently
found as a comorbidity among patients with ASD and, in
fact, many genes are associated with both conditions, we
next considered only Sfari genes that are not associated with
ID to address the modules specificity to ASD. This analysis
revealed an enrichment for ASD-exclusive genes (“Sfari
only”) again in the same three modules, whereas no
enrichment was found for “ID all” or “ID only” genes in
any module (Fig. 5a, Supplementary Table S12). Remark-
ably, MNeu2-tan is the only module enriched for genes
associated with both ASD and ID (Fig. 5a, “Sfari/ID
overlap”, FDR= 4.3 × 10−5, OR= 4) and it is slightly more
enriched for “Sfari all” genes (OR= 2.7) than for “Sfari
only” genes (OR= 2.09), suggesting a possible association
of this module with comorbid ID. Collectively, the high
frequency of LoF mutations and the enrichment for Sfari
genes in MNeu1-turquoise bring support to the association of
this module to ASD.
The synapse-related module MNeu1-turquoise has
been consistently associated with ASD in several
independent gene expression studies using
neuronal cells
In order to validate our findings, we next asked whether the
ASD-associated modules identified in this study were also
found as disease-associated in other expression studies
conducted with ASD neuronal cells either obtained from
postmortem brains [8–10, 39] or derived from iPSC
[16, 17, 19]. We also compared our results to the modules
identified in fetal/neonatal brain samples from BrainSpan
database that are enriched for ASD candidate genes [38]
Fig. 3 Modules of co-expressed genes in NPC and neurons are
dysregulated in ASD. a–d Network analysis dendrogram showing
clustering of genes based on topological overlap for identification of
modules of co-regulated genes in iPSC-derived NPC (a) and neurons
(c) and z-scores of preservation of such modules in transcriptome data
from fetal brain samples (b for NPC modules and d for neuron
modules). e, h, k Module eigengenes for MNPC10-blue, MNeu18-pur-
ple, and MNeu1-turquoise showing, respectively, upregulation, down-
regulation, and upregulation of these modules in ASD (red) compared
with control (turquoise) samples. f, i, l Functional annotation enrich-
ment analysis for the three ASD-associated modules. g, j, m
Protein–protein interaction networks showing biological evidence of
interaction of the 200-top genes assigned to each of the co-expression
networks identified by WGCNA. Not connected nodes were hidden.
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and to modules identified in blood samples from ASD
patients [37], to verify whether the dysregulation of any of
the ASD-associated modules could be detected in an easily
accessible tissue (Fig. 5b; Supplementary Table S13).
Although MNPC10-blue showed a significant overlap
with modules identified by other studies using postmortem
brains and iPSC-derived neurons (Fig. 5b, Supplementary
Table S13), these MNPC10-blue correspondent modules
were not found as ASD-associated in any of such studies
(ASD-associated modules are denoted by an asterisk in
Fig. 5b). Concordantly, we identified a module in iPSC-
derived neurons, MNeu19-greenyellow, that also has a sig-
nificant overlap with MNPC10-blue (p= 7.3 × 10−13; OR=
13.11; data not shown) but it is not dysregulated in our
cohort of patients compared with controls. On the other
hand, MNPC10-blue shows a significant overlap with a
module identified as upregulated in blood of autistic
patients (mod midnightblue, p= 8.3 × 10−14, OR= 13.18).
MNeu18-purple has a moderate overlap with module red
from Mariani et al. [16] (p= 0.001, OR= 2.76), which is
not associated with ASD, and with module M3 from Par-
ikshak et al. [38] (p= 3.3 × 10−5, OR= 3.37) which, in
turn, is enriched for de novo variants found in ASD indi-
viduals (Fig. 5b).
MNeu1-turquoise also has a significant overlap with a
module enriched for de novo protein-disrupting variants
seen in ASD [38], the module M16 (p= 7.7 × 10−14, OR=
4.09, Fig. 5b). Most importantly, MNeu1-turquoise has a
very strong overlap with modules identified as dysregulated
in ASD in all selected expression studies using neuronal
cells (Fig. 5b): M12 from Voineagu et al. [8] (p= 2.8 ×
10−14, OR= 5.33), mod1 and mod6 from Gupta et al. [9]
(p= 8.2 × 10−31, OR= 3.82 and p= 7.5 × 10−5, OR=
2.49, respectively), CTX16, CTX10, and CTX4 from Par-
ikshak et al. [10] (p= 2.5 × 10−9, OR= 4.22; p= 0.01;
OR= 2.85; p= 0.01, OR= 2.91, respectively), CD1 and
CD13 from Gandal et al. (p= 3.3 × 10−22, OR= 4.5 and
p= 8.5 × 10−5, OR= 5.99, respectively), modules brown
and blue from Mariani et al. [16] (p= 1.1 × 10−48, OR=
6.45 and p= 0.01, OR= 1.84, respectively), M19d35 from
Fig. 4 Putative molecular links between ASD dysregulated mod-
ules in NPC and neurons. Differentially regulated proteins in NPC
that act as upstream regulators of a significant number of genes from
MNeu1-turquoise (yellow outline) and that have expression levels
significantly correlated with MNPC10-blue and MNeu1-turquoise/
MNeu18-purple eigengenes (orange outline) are shown in the center of
the figure. EIF4H, which is dysregulated in transcription and protein
levels, is marked in blue as this molecule is also a member of MNPC10-
blue. These proteins are connected with genes from the three ASD-
associated modules which they are known to interact with.
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De Rosa et al. [19] (p= 1.7 × 10−15, OR= 11.74) and
module lightyellow (TM1) from Schafer et al. [17] (p=
10−80, OR= 8.73). Curiously, while the modules brown
and blue from Mariani’s study, M19d35 from De Rosa’s
study and module lightyellow (TM1) from Schafer’s study,
which were all also conducted in iPSC-derived neurons, are
upregulated in ASD individuals such as the MNeu1-
turquoise in the present study, the ASD-associated mod-
ules identified in postmortem brain tissue are downregulated
in the patients. These results show the reliability of MNeu1-
turquoise as an ASD-associated module of co-expressed
genes, since it has been consistently detected as
differentially expressed in a series of studies that either used
ASD postmortem brain samples or iPSC-derived neuronal
cells.
Finally, we sought to further refine the list of genes
within MNeu1-turquoise, capturing only those genes with a
strong evidence of being part of this module. For this pur-
pose, we identified which genes were consistently assigned
to any of the modules with significant overlap with MNeu1-
turquoise in all the studies that used either fetal/neonatal
brain samples or iPSC-derived neurons [16, 17, 38]
(Fig. 5c; see the Materials and methods section). Remark-
ably, this approach seems to prioritize ASD-risk genes,
since the list of 83 genes found in this overlap is more
enriched for Sfari genes than the lists of the original mod-
ules (Fig. 5c; Table 1; Supplementary Table S13), sug-
gesting that this set of genes should be carefully examined
in exome sequencing from ASD patients.
Discussion
Analysis of differential transcriptional profile can be useful
to detect more homogeneous biological alterations among
ASD individuals, helping to uncover pathways consistently
Fig. 5 Consistent association of MNeu1-turquoise with ASD. a
Genetic evidence for MNeu1-turquoise involvement in ASD patho-
physiology: the top part of the panel shows the burden of de novo
potentially damaging LoF and missense variants in ASD cohort for the
indicated modules, while the bottom part shows enrichment for Sfari
and/or ID related genes. Heatmap colors refers to FDR values of
enrichment trend. Odds-ratio values are only plotted for those modules
that showed enrichment for genes in the denoted category (FDR <
0.05; OR > 1), except for the burden of ASD patients harboring LoF
variants in MNeu1-turquoise (☨) which, although not statistically sig-
nificant, presented a clear trend of enrichment. FDR and OR values for
the full set of modules are available in Supplementary Table S12.
b Module overlap analysis comparing the three ASD-associated
modules identified in this study with a series of transcriptome studies
conducted either with postmortem brain samples or iPSC-derived
neuronal cells (as indicated by the legend at left). All the modules that
presented significant overlap with MNPC10-blue, MNeu1-turquoise, or
MNeu18-purple (FDR < 0.05, OR > 1) are shown and modules asso-
ciated with ASD in each of the selected studies are indicated by an
asterisk. Modules correspondent to MNPC10-blue were identified in all
the selected studies and, although not associated with ASD in none of
the studies conducted with neuronal samples, it was detected as dys-
regulated in ASD patients in a metanalysis investigation of blood
transcriptome. A MNeu18-purple correspondent module was identified
in fetal brain samples and such module was found as enriched for LoF
damaging variants present in ASD patients. MNeu1-turquoise corre-
spondent modules were identified in all the studies and, in all of them,
they were found as dysregulated in ASD patients. Heatmap colors
refers to FDR values of enrichment trend and odds-ratio values are
plotted (FDR < 0.05; OR > 1). For detailed overlap analysis, refers to
Supplementary Table S13. c Venn-diagram showing the number of
genes in overlap between the different MNeu1-turquoise correspondent
modules identified in studies conducted with either fetal neuronal brain
or iPSC-derived neurons.
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compromised in patients [46, 47], to interpret which geno-
mic variants might have stronger functional effects and,
ultimately, may allow the identification of diagnostic bio-
markers. Because ASD is an extremely heterogeneous dis-
ease, the investigation of different subgroups of patients
regarding genetic underlying causes, functioning level and
comorbidities will be important to understand whether they
share common transcriptome alterations or whether parti-
cular expression differences can be attributed to each of
these groups.
Here, we analyzed the transcriptome of iPSC-derived
NPC and neurons of controls and an ASD sample enriched
with high-functioning normocephalic patients in whom the
disease probably follows an oligogenic or polygenic pattern
of inheritance, as we did not identify any rare de novo
potentially damaging loss-of-function mutation that could
account in isolation for the disease in these individuals. This
is in agreement with previous data showing that de novo
damaging variants are more associated with lower IQ
[32, 48], giving further support to the hypothesis that high-
functioning patients most probably follow complex pattern
of inheritance, where medium to low risk inherited variants
may play a major role.
We validated our transcriptional data demonstrating that
they are comparable to transcriptional profiles of human
fetal brains, and the transition from iPSC-derived NPC to
neurons indeed mimics the temporal progression of in vivo
brain development, since the gene expression signature of
NPC correlates with an earlier period of gestation compared
with neurons. Particularly, our 4 weeks long differentiation
protocol generated neurons showing a transcriptional sig-
nature whose the highest correlation is with a temporal
window of development that seems to be critical for ASD
pathophysiology, since there is an enrichment of ASD-
associated genes among genes expressed during this period,
as previously proposed [45]. Our study reinforces the con-
clusion made by these authors, since we demonstrate that,
indeed, there are important differences in gene expression of
ASD individuals in this time point. The correlation with
mid-early fetal brain expression profile has already been
shown by another study using ASD iPSC-derived neurons
[16], which was conducted using 3D neuronal organoids.
Thus, our results suggest that iPSC-derived neurons at the
fourth week of differentiation generated on 2D is a suitable
model to explore transcriptional dysregulation in ASD or
other neurological conditions whose the critical time period
for disease pathophysiology is the mid-early gestational
period.
To identify genes with differential expression, we used a
statistical method that accounts for the repeated measures of
different clones of a same individual, which is an important
aspect of the design of the experiments in iPSC field that is
often neglected. Although few genes reached statistical
significance for differential expression in ASD neuronal
cells, which is in agreement with the complexity of the
disease, the top ranked upregulated genes showed enrich-
ment within functions and pathways relevant for ASD.
Our systems biology approach revealed expression dys-
regulation in NPC from ASD individuals, showing that there
might be molecular alterations in earlier neurodevelopmental
phases in these patients as well. Whereas the co-expression
module dysregulated in ASD NPC, MNPC10-blue, is not
enriched for Sfari genes and the frequency of ASD indivi-
duals harboring disrupting variants in genes of this module is
not different from controls, thus lacking genomic evidence
of its involvement in ASD pathophysiology, a similar
module was identified as dysregulated in a meta-analysis of
transcriptome studies conducted in the blood of autistic
patients [37]. Thus, the expression levels of core genes
within this network should be further explored in blood, in
order to verify if they might be potentially used as a bio-
marker for the disease. Curiously, although MNPC10-blue is
preserved in neurons according to our module overlap ana-
lysis, it is not dysregulated in this type of cells in ASD
individuals, suggesting that its expression levels are nor-
malized in the patients once NPC differentiate to neurons.
Table 1 Enrichment for Sfari
genes in each of the MNeu1-
turquoise correspondent
modules identified in the
denoted studies.
Study Module Sfari genes Total genes
in module
% of
Sfari genes
Odds-
ratio
Padj
Griesi-Oliveira MNeu1 44 506 8.7% 2.07 0.0001
Mariani et al. [16] Brown 113 1033 10.9% 3.07 3 × 10−19
Blue 80 1354 5.9% 1.44 0.007
pink 37 654 5.7% 1.34 0.14
tan 19 404 4.7% 1.09 0.81
Parikshak et al. [38] M13 37 699 5.3% 1.28 0.21
M16 45 455 9.9% 2.59 1 × 10−6
M17 57 810 7.0% 1.78 0.0004
Schafer et al. [17] Lightyellow 49 1305 3.8% 1.03 0.81
Consensus module 12 83 14.5% 3.33 0.001
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MNPC10-blue is enriched for genes involved in protein
synthesis, a cellular process already implicated in ASD
pathophysiology (reviewed in Bourgeron [6]). We hypo-
thesized that its expression alteration could dysregulate the
levels of particular proteins which, during neuronal dif-
ferentiation process, would control expression of hub
genes that are important for the establishment of MNeu1-
turquoise and MNeu18-purple co-expression modules, the
two networks found as ASD-associated in neurons. Indeed,
using proteomic analysis, we identified some potential
molecular links between these three modules, such as
EWSR1, APP and EIF4H. Particularly, EIF4H is one of
the genes deleted within 7q11.23 in patients with Williams
Syndrome, which shares some phenotypic characteristics
seen in ASD [49], while altered levels of APP and its
metabolites have been identified in brain and plasma from
autistic patients [50]. Although these results should be
interpreted with cautious due to the limited number of
samples included in this analysis, these possible molecular
regulatory links between modules in NPC and in neurons
deserve further investigation.
Alternatively, the upregulation of MNeu1-turquoise, a
module of synapse genes, and downregulation of MNeu18-
purple, which is enriched for translation related genes, could
be induced primarily by genetic variants in genes belonging
to these modules. Although we have not found a statistically
significant excess of ASD individuals with disrupting var-
iants in genes from MNeu1-turquoise and MNeu18-purple
compared with controls, we did observe a clear trend toward
this enrichment in MNeu1-turquoise. Also, other studies
have found enrichment of genes harboring de novo LoF
variants identified in ASD individuals in modules that
overlap MNeu1-turquoise and MNeu18-purple (M16 and M3,
respectively, in Parikshak et al. [38] and replicated by
Takata et al. [51]). On the other hand, considering that our
transcriptome analysis was done in non-monogenic ASD
cases (as it is the case of other studies such as Mariani et al.
[16] and Schafer et al. [17]), it is likely that the de novo
variants are actually not a major driving factor for expres-
sion alteration of these genes, and rare and/or common
inherited variants might also play a role in the regulation of
the modules. Accordingly, different studies have shown that
MNeu1-turquoise correspondent modules are enriched for
ASD positive GWAS signals [8–10, 39]. In addition,
Schafer and colleagues [17] have recently demonstrated that
ASD NPC present altered chromatin accessibility in close
distal regions of genes from the MNeu1-turquoise corre-
spondent module identified in their study (lightyellow-
TM1), which could be explained by variants in such reg-
ulatory elements. The distribution of rare inherited variants
across these modules, particularly in regulatory regions,
should be further explored in large genome sequencing
studies that are being conducted in order to provide a better
comprehension of the primary mechanisms driving their
expression alterations.
We also found an enrichment of Sfari genes in MNeu1-
turquoise, reinforcing the body of evidence to support the
association of this module with ASD. In addition, MNeu1-
turquoise is enriched for genes related to synaptic trans-
mission, voltage-gated channels function, dendrite extension
and neuronal signaling. Our neuronal morphological analy-
sis showed that ASD individuals have less arborized neurons
with shorter neurites, and these phenotypic alterations
slightly improve when ASD neurons are co-cultivated with
control neurons. Similar morphological alterations were
already found in other syndromic and non-syndromic ASD
individuals [11, 14, 52]. Other studies have also reported
altered excitability and synaptic function in idiopathic ASD
iPSC-derived neurons [15, 53, 54]. These results give
functional support for the role of MNeu1-turquoise expres-
sion dysregulation in ASD pathophysiology.
Moreover, comparing our results with multiple tran-
scriptome studies of neuronal cells, we found that MNeu1-
turquoise has a strong overlap with ASD-associated mod-
ules identified by all these studies, revealing the consistent
association of this co-expression network of synapse genes
with ASD. Interestingly, this module has been consistently
found as upregulated in iPSC-derived neurons [16, 17, 19]
and downregulated in postmortem brain tissue [8–10, 39].
Some hypotheses can be formulated to try to explain this
apparent discrepancy: first, postmortem brain tissue is a
mixture of different cell types, including neurons and glial
cells. If the brains of ASD individuals have fewer neurons
than controls, an upregulation of the module can be masked
by the reduced number of neurons, inducing a misleading
interpretation of a downregulation of the module. The use of
a normalization method accounting for the proportion of
neurons, as applied here, to analyze postmortem brain data
would help to address this hypothesis. On the other hand, it
has been shown that MNeu1-turquoise correspondent mod-
ules (represented by M13, M16, and M17 in Parikshak et al.
[38] and M15 in Kang et al. [24]) present a gradual increase
in expression from the early fetal period until around 1–2
years old, when the module expression reaches a plateau. In
parallel, a recent study identified heterochronic dynamics in
the regulation of this module of synaptic genes, which
initiates the increase in expression much earlier in ASD
individuals than in controls [17]. It might be possible, then,
that an overexpression of MNeu1-turquoise at an improper
period of neurodevelopment would induce a negative
feedback of regulation, repressing these genes later on, or
refraining their continuous increased expression, leading to
the downregulation of the module postnatally.
Importantly, this module has been identified as dysre-
gulated in iPSC-derived neurons regardless the endophe-
notype that was studied (macrocephalic patients in Schafer
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et al. [17] and Mariani et al. [16], low-functioning patients
in DeRosa et al. [19], and high-functioning patients in the
present study), suggesting that this network is a core
module for ASD pathophysiology. Whether other discrete
transcriptional alterations can distinguish different endo-
phenotypes is a question that remains to be explored. In this
regard, it will be important that different studies use stan-
dardized methods and provide a detailed clinical and genetic
characterization of the sample, in order to allow a reliable
comparison across the studies. We found some interesting
results that may guide future efforts attempting to address
this question. For instance, we found genetic evidence
supporting the association of MNPC1-turquoise with ASD, a
module not dysregulated in patients’ NPC in our expression
analysis, which is enriched for genes related to chromatin
regulation. Interestingly, abnormal chromatin accessibility
was recently identified in NPC from ASD macrocephalic
individuals [17]; therefore, it would be worthy to investigate
if this module is particularly dysregulated in this subset of
patients. In addition, a module that is not dysregulated in
ASD neurons in our sample, MNeu2-tan, was found as
particularly enriched for Sfari genes that are also related to
ID, differently than MNeu1-turquoise. These results, along
with the fact that our sample is enriched with high-
functioning patients, suggest that dysregulation of MNeu2-
tan might contribute to ID as a comorbidity in ASD, and
deserve further investigation in samples enriched with low-
functional individuals. Finally, it is interesting to notice that
modules of co-expressed genes related to immune response
have been consistently found as dysregulated in ASD
postmortem brain tissue [8–10, 39], while in transcriptome
studies with iPSC-derived neurons, they have not. Since this
module is associated with glial markers, this result may be
due to a low proportion of glial cells in the samples derived
from iPSC (and particularly, in our case, this could have
been even more minimized due to the normalization step
based on the proportion of neurons that we have con-
ducted). Future complementary transcriptome analyses on
iPSC-derived glial cells are worthy to explore whether the
in vitro model will also reflect the dysregulation of this
immune response module that is seen in postmortem brains,
as it is the case for the module of synapse genes. Another
unexplored question worthy to be pursued is whether dif-
ferential splicing events can also be detected in iPSC-
derived neuronal cells, possibly reflecting what happens
during a fetal period, as it has been seen in transcriptome
analysis of ASD postmortem brains [55].
Although the small sample size imposes some limits to
this study, taken together, our results support the idea that
ASD patients are very homogeneous relatively to the
expression profile of the module of synapse genes, MNeu1-
turquoise, since it has been identified as dysregulated in
a series of transcriptome studies, regardless the
endophenotypic group analyzed. The dysregulation of this
module of co-expressed synaptic genes can be considered
one of the most consistent findings to be demonstrated to
date for ASD, suggesting its central role for the disease
pathophysiology. Therefore, this module should be care-
fully considered when exploring genetic variants in ASD
individuals, its expression pattern might be used as a bio-
marker for the disease and, specially, it should be explored
as a potential target for disease treatment.
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